Hepatitis B immune globulin preparations and use in liver transplantation
Clinics in Liver Disease, ISSN: 1089-3261, Vol: 7, Issue: 3, Page: 537-550
2003
- 37Citations
- 30Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations37
- Citation Indexes37
- 37
- CrossRef34
- Captures30
- Readers30
- 30
Review Description
Hepatitis B immune globulin remains a central component of prophylaxis in HBV-infected patients undergoing liver transplantation. HBIG monotherapy given at a high dosage and indefinitely can prevent recurrence in 65% to 80% of patients. Because treatment failures occur and combination therapy using HBIG plus a nucleoside analog is more uniformly effective, the current standard of care is combination HBIG plus a nucleoside analog. These combination protocols have reduced the rate of virologic breakthrough to 10% or less. Several questions remain. The optimal dose and duration of HBIG use is unclear. Moreover, the development of resistance to lamivudine (and other nucleoside analogs) before transplantation increases the risk for virologic breakthrough post-transplantation. For patients with pre-transplant evidence of active HBV replication caused by the presence of nucleoside analog resistance, HBIG may be the main or only form of prophylaxis. For these patients, HBIG doses sufficient to maintain anti-HBs titers comparable to the days of HBIG monotherapy seem warranted. New HBIG formulations have made anti-HBs therapy more safe and tolerable to patients but the cost of the drug remains significant. The cost factor is particularly important in developing countries or countries with more limited resources for management of liver transplant recipients. Thus, there remains a need to develop and test new forms of anti-HBs therapy, so that effective but less expensive forms of immunoprophylaxis can be made available.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S108932610300045X; http://dx.doi.org/10.1016/s1089-3261(03)00045-x; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0042835575&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/14509525; https://linkinghub.elsevier.com/retrieve/pii/S108932610300045X; http://linkinghub.elsevier.com/retrieve/pii/S108932610300045X; http://api.elsevier.com/content/article/PII:S108932610300045X?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S108932610300045X?httpAccept=text/plain; http://dx.doi.org/10.1016/s1089-3261%2803%2900045-x; https://dx.doi.org/10.1016/s1089-3261%2803%2900045-x
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know